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BACKGROUND. The acknowledged effectiveness of vinblastine, bleomycin, and
methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lym-
phoma has been associated with conﬂicting toxicity reports.
METHODS. One hundred forty-three patients were evaluated clinically and had
favorable Stage IA or IIA Hodgkin lymphoma. Ninety-three patients were treated
with the standard VBM schedule combined with extended-ﬁeld radiotherapy (EF-
RT), leaving the choice of the therapeutic sequence free. Fifty subsequent patients
were treated with a slightly modiﬁed VBM schedule (VbMp) combined with RT
limited to involved ﬁelds (IF-RT) and delivered only after the end of chemotherapy.
In the VbMp schedule, intervals between cycles were 21 days instead of 28 days,
bleomycin doses were reduced, small doses of prednisone were given orally, and
the interval before RT was prolonged.
RESULTS. Clinical response was complete in 96% of patients who were treated with
VBM plus EF-RT and in 94% of patients who were treated with VbMp plus IF-RT.
Recurrence rates were nearly identical (12% and 11%, respectively) over necessarily
different follow-up (91 months and 33 months, respectively). Hematologic toxicity
was tolerable in both trials, and pulmonary side effects were moderate in the ﬁrst
trial and negligible in the second. On the whole, treatment was tolerated better
when RT followed chemotherapy.
CONCLUSIONS. The VBM regimen was conﬁrmed to be effective in patients with
early-stage Hodgkin lymphoma. Administration of all cycles before RT improved
tolerance; pulmonary toxicity probably is mitigated further by reduced bleomycin
doses, mild prednisone therapy, and a more prolonged resting interval before RT.
A slightly higher recurrence rate was expectable in the VBM plus IF-RT trial despite
the actual intensiﬁcation of vinblastine and methotrexate. Cancer 2003;98:
2393–401. © 2003 American Cancer Society.
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There is general consensus on the use of the doxorubicin, bleomy-cin, vinblastine, and dacarbazine (ABVD) multiple-drug chemo-
therapy (CT) regimen combined with radiation therapy (RT) in the
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management of patients with early-stage Hodgkin
lymphoma (HL).1 Thus, a variable number of ABVD
cycles combined with variably limited irradiation
doses and ﬁelds are employed in these patients ac-
cording to more or less favorable clinical presentation.
It has been shown that this approach strongly reduces—
and even abates—the recurrence rate. Subsequent
work must focus on reducing toxicity without limiting
effectiveness. To this aim, the efﬁcacy of so-called
neoadjuvant CT suggests that limited irradiation ﬁelds
may be used in the combined-modality approach. In
contrast, other drug regimens, such as vinblastine,
methotrexate, and bleomycin2 (VBM); epirubicin,
bleomycin, vinblastine, and dacarbazine3 (EBVD); and
methotrexate, vinblastine, and prednisolone4 (MVP),
have been tested in combination with RT.
VBM has been adopted in several clinical trials in
the last 15 years, and a large amount of evidence of its
effectiveness has been collected. However, some con-
cerns still are present regarding its (mainly pulmonary)
toxicity due to conﬂicting results that have emerged
from different clinical trials. Because our preliminary
experience5 with the this regimen in patients with early-
stage Hodgkin disease was judged positive, with a favor-
able balance between effectiveness and toxicity, in 1996,
the Gruppo Italiano Studio Linfomi (GISL) decided to
close the trial with the standard VBM schedule com-
bined with extended-ﬁeld RT (EF-RT) and to investigate
a therapeutic combination with a few substantial mod-
iﬁcations with the objective of further limiting the ex-
pected subacute and late toxicity. Changes included
completion of the whole CT schedule before RT, inten-
siﬁcation of vinblastine and methotrexate with a reduc-
tion of the total bleomycin dose, the addition of a mild
prednisone medication after every antitumor drug ad-
ministration, ﬁnally, limitation of RT to the involved
ﬁelds (IF-RT). Intensiﬁcation of vinblastine and metho-
trexate was meant to prevent that response from being
diminished by restriction of RT, whereas bleomycin re-
duction and prednisone addition to the CT schedule
were intended to mitigate the expected pulmonary tox-
icity. For the same reason, the interval between the end
of CT and the start of RT was prolonged to 4–6 weeks.
Herein, we report the results of the new trial, MH-1b,
which was initiated in 1996, and provide an update on
the results of the previous trial, MH-1, in which the
accrual was prolonged—after the interim analysis that
led to the preliminary report referred to above–until the
start of the subsequent MH-1b trial.5
MATERIALS AND METHODS
Patient Populations and Staging Procedures
The GISL coordinated two subsequent nonrandom-
ized multicenter studies of patients with early-stage,
favorable HL: MH-1 started in January 1988 and closed
in December 1995, and MH-1b ran from January 1996
until December 2001. The patients on both protocols
were treatment-naive, human immunodeﬁciency vi-
rus–negative patients with biopsy-proven Hodgkin
disease with a histologic type other than lymphocyte-
depleted nodular sclerosis or lymphocyte depletion.
These patients had clinical Stage IA or IIA HL accord-
ing to the Cotswolds meeting6 criteria and had no
more than 3 involved sites, an erythrosedimentation
rate  40 mm during the ﬁrst hour, and no bulky
masses (according to the Cotswolds recommenda-
tions, a tumor mass was considered bulky if it mea-
sured  10 cm and was located extramediastinally; or,
in tumors with a mediastinal location, when its max-
imum width was equal to or greater than one-third of
the internal transverse dimension of the thorax at the
level of the ﬁfth and sixth thoracic vertebrae). Due to
the planned intensiﬁcation of 2 of the 3 VBM drugs,
inclusion in the MH-1b trial was restricted to patients
younger than age 65 years, and the acceptable lower
limit of performance status was deﬁned by a Karnof-
sky score of 50. Patients with involvement below the
diaphragm were not excluded. Two patients with ex-
tranodal involvement also were enrolled in the MH-1
study. Informed consent was obtained from each pa-
tient.
Staging was strictly clinical and included medical
history, physical examination, laboratory tests, chest
X-ray examination, abdominal ultrasound, computed
tomography scans of chest and abdomen, and unilat-
eral bone marrow core needle biopsy. Lymphangiog-
raphy was not performed. The primary clinical data on
patients from both studies are reported in Table 1. All
staging procedures performed at initial assessment
were repeated after therapy, with the exception of
bone marrow biopsy. A complete remission (CR) was
deﬁned as complete regression of measured lesions
and the disappearance of all other objective evidence
of lymphoma for at least 3 months. Partial remission
(PR) consisted of a decrease  50% in the sum of the
products of the greatest dimensions of measurable
lesions. No response (NR) was a decrease  50% in
measurable lesions; and, ﬁnally, progressive disease
(PD) was an increase in the size of at least 1 measur-
able lesion, or the appearance of at least 1 new lesion,
or the recurrence of symptoms.6
One hundred two patients were included in the
MH-1 trial. Three patients with misdiagnosed stage
IIIA disease, two patients with mediastinal bulk, three
patients with histologic types other than those re-
quested, and one experienced patient were excluded
due to protocol violations. Six of 93 eligible patients
were older than age 65 years, because there was no age
2394 CANCER December 1, 2003 / Volume 98 / Number 11
restriction in the MH-1 trial; their characteristics are
listed separately in Table 1 to allow better comparison
of the data on patients from the same age group in
both studies. Of the 87 patients age 65 years and
younger, 43 patients received RT before VBM, and 41
patients underwent the reversed sequence; 3 patients
were treated with 3 CT cycles before and the other 3
CT cycles after interposed irradiation. The median
follow-up was 91 months (range, 15–170 months). The
preliminary results from the ﬁrst 50 assessable pa-
tients were reported in 1996,5 with a median follow-up
of 38 months.
Fifty-seven patients were enrolled in the MH-1b
study. Fifty patients were assessable for clinical re-
sponse and toxicity and have been included in this
report after a median follow-up of 33 months (range,
6–68 months).
Chemotherapy
A VBM-based, combined CT-RT schedule was admin-
istered in both protocols. In the ﬁrst trial (MH-1), the
original VBM regimen associated with EF-IR was
adopted, but it left clinicians free to choose the CT and
RT sequence in each patient. In the second trial (MH-
1b), a VBM variant was used (VbMp) with intensiﬁed
doses of vinblastine and methotrexate and reduced
doses of bleomycin—invariably followed by IF-RT.
Both the original VBM schedule and the VbMp
schedule are reported in Table 2. In both trials, the
criteria for dose adjustments based on acute hemato-
logic toxicity were the same as the criteria reported by
Horning et al. in their ﬁrst report.2 Dose escalations
were not allowed. Dose intensity was calculated for
each drug and for the whole regimen according to the
criteria reported by Hryniuk7 and the examples re-
ported by DeVita et al.8 According to these calcula-
tions, the planned dose intensiﬁcation in the VbMp
schedule was 1.31 for vinblastine and methotrexate
and 0.79 for bleomycin, with an average dose intensity
of 1.13 for the whole regimen.
Radiotherapy
RT was administered by megavoltage equipment in
different RT divisions but with different strategies in
the two trials. In the MH-1 study, RT consisted of
subtotal lymphoid irradiation (STLI), including mantle
and paraaortic-splenic pedicle ﬁelds for patients with
supradiaphragmatic presentation and complete in-
verted Y ﬁeld irradiation (including the spleen) for
patients with subdiaphragmatic disease. In the MH-1b
study, only involved ﬁelds were irradiated, and RT was
delivered to one or more of the six lymphatic areas
above the diaphragm (Waldeyer ring, bilateral cervical
and axillary lymph nodes, mediastinum) or to the ﬁve
lymphatic areas below in patients with subdiaphrag-
matic involvement (paraaortic, bilateral iliac, and in-
guinal). In the two patients with subdiaphragmatic
presentation in the MH-1b trial, the spleen was not
involved and, thus, was spared. The boundaries of the
irradiation ﬁelds were set 5 cm beyond the areas clin-
ically evaluated as involved. Mediastinal irradiation
also included the pulmonary hila with external mar-
TABLE 1
Clinical Staging Characteristics of the Patient Populations in the Two
Gruppo Italiano Studio Linfomi Trialsa
Characteristic
MH-1 trial MH-1b trial
Age < 65 yrs Age > 65 yrs Age < 65 yrs
Gender (no. of patients)
Male 57 3 28
Female 30 3 22
Age (yrs)
Mean  SD 36.9  13.8 71.8  3.2 33.5  11.9
Range 16–63 67–79 18–64
Karnofsky performance status
Median 100 90 100
Range 70–100 70–100 80–100
Stage (no. of patients)
IA 26 2 14
IEA 2 2 0
IIA 59 2 36
Subdiaphragmatic
presentation
(no. of patients) 4/87 0/6 2/50
Histology (no. of patients)
Lymphocyte predominance
(nodular/diffuse) 14 1 5
Common variety
Nodular sclerosis,
undeﬁned 11 1 7
Nodular sclerosis, cellular 32 0 23
Lymphocyte-rich 3 0 1
Mixed cellularity 27 4 14
Hemoglobin (g/dL)
Mean  SD 14.0  1.5 13.4  0,8 13.5  1.6
Range 11.6–17.5 11.9–14.9 10.0–17.6
Lactate dehydrogenase
(mU/mL)
Mean  SD 341  180 333  84 329  78
Range 103–1449 195–522 140–546
Erythrocyte sedimentation rate
(mm/hr)
Mean  SD 16.4  9.8 18.5  12.5 15.9  11.8
Range 2–37 6–37 2–39
Serum albumin (g/dL)
Mean  SD 4.32  0.44 4.20  0.52 4.24  0.51
Range 3.49–5.80 3.50–4.70 3.00–5.28
Follow-up (mos)
Median 91 59 33
Range 15–170 12–100 6–68
SD: standard deviation; mU: milliunits.
a Six elderly patients who were enrolled in the MH-1 trial are listed separately.
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gins of 1–2 cm on healthy lung tissue. In both studies,
the recommended doses were 36–40 grays (Gy), but
unavoidable differences in source, energy, dose frac-
tion, total dose, and ﬁeld area had to be tolerated from
institution and institution.
Toxicity Assessment
Toxicity was measured according to standard Eastern
Cooperative Oncology Group (ECOG)9 criteria. Due to
the preceding experience with VBM, standard chest
radiography was the basic test to evaluate and moni-
tor possible pulmonary toxicity from bleomycin and
RT. For this purpose, a ﬁne reticular inﬁltrate at the
base of the lungs, alveolar interstitial bibasilar inﬁltra-
tion, progressive lower lobe involvement, and lobar
consolidation, respectively, were taken as further
grades of toxicity when associated with corresponding
symptoms. Pulmonary function tests and measure-
ment of single-breath carbon monoxide diffusing ca-
pacity were performed only on demand, when respi-
ratory symptoms (mainly cough and/or dyspnea) were
not related to unequivocal lesions on standard chest
radiographs.
Statistics
Toxicity grades were managed statistically as ranks of
observations ordered by increasing magnitude and
analyzed with the Mann–Whitney U test.10 Overall
survival (OS) was calculated from the date of diagnosis
to the date of last observation or death. Failure-free
survival (FFS) was measured from the start of treat-
ment to one of the following events: disease progres-
sion during treatment, incomplete remission at the
end of treatment, recurrence, or death due to the
disease.11 A partial remission (PR) and a null response
(NR) were considered to be events, because they often
hide a resistant or refractory tumor component12 and
actually share most of the therapeutic requirements13
for early recurrences, which currently are considered
unquestionable events for statistical purposes. Curves
were calculated according to the Kaplan–Meier meth-
od,14 and deaths due to causes other than HL were not
censored.
RESULTS
The clinical and staging characteristics of the patients
in the two studies were very similar (Table 1). Table 3,
which reports the responses after combined treat-
ments, shows that there were no differences in clinical
outcome between the two protocols nor within the
MH-1 trial relative to the adopted CT-RT sequence.
Some differences were observed in the dose in-
tensities of the administered drugs. Relative to the
doses planned in the respective schedules, VBM and
VbMp had similar dose intensities—0.89  0.18
(range, 0.47–1.36) and 0.94  0.11 (range, 0.59–1.15),
respectively. Referencing the actual VbMp doses and
times of administration to those planned in the orig-
inal VBM schedule, the mean relative dose intensity of
VbMp was 1.07  0.13, corresponding to an actual
mean intensiﬁcation of about 20%. This ﬁgure results
from combining the actual 27–50% intensiﬁcation in
vinblastine and methotrexate with the 10–22% de-
crease in bleomycin dose intensity. Table 4 shows the
comparative dose intensity for each drug and for the
whole regimen after normalization to the VBM doses;
the MH-1 results are grouped further according to
whether RT preceded or followed CT. The results dem-
TABLE 2
Schedules of the Two Slightly Different Vinblastine, Bleomycin, and Methotrexate Regimens Used in the Gruppo Italiano Studio Linfomi MH-1
and MH-1b Protocols
MH-1 protocol: VBM  EF-RT MH-1b protocol: VbMp  IF-RT
Drug Dose (mg/m2) Route Day(s) Recycle (days) Dose (mg/m2) Route Day(s) Recycle (days)
VBL 6 I.V. 1, 8 28 6 I.V. 1, 8 21
Bleo 10 I.V. 1, 8 28 6a or 4b I.V. 1, 8 21
MTX 30 I.V. 1, 8 28 30 I.V. 1,8 21
Pred — — — — 25c Oral 1–5, 8–12 21
RT SLRTd (30–40 Gy) — — — IF-RTe (30–40 Gy) — —
VBM: vinblastine, bleomycin, and methotrexate; EF-RT: extended-ﬁeld radiotherapy; VbMp: modiﬁed VBM schedule; IF-RT: involved-ﬁeld radiotherapy; VBL: vinblastine; I.V.: intravenous; Bleo: bleomycin; MTX:
methotrexate; Pred: prednisone; SLRT: subtotal lymphoid irradiation: radiotherapy; Gy: grays.
a Cycles 1 and 2.
b Cycles 3–6.
c Fixed dose.
d SLRT administered before/after/sandwiched between VBM.
e IF-RT administered 25–40 days after VBM.
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onstrate that, in the MH-1 trial, the administered dose
intensity of all drugs was signiﬁcantly higher when CT
preceded RT compared with when CT followed RT.
Hematologic toxicity was fully tolerable, as shown
in Table 5. The highest toxicity grades (Grades 3–4)
were recorded in the MH-1 trial with the RT  CT
sequence. In all, the blood cell count was decreased
more in the group treated with CT after RT than vice
versa. This was demonstrated in the MH-1 trial by the
signiﬁcant difference among grades of neutropenia or
by the difference in the grades of anemia according to
the adopted CT and RT sequence; an indirect conﬁr-
mation also comes from the higher doses of myelo-
TABLE 3
Response and Recurrence Rates from the MH-1 Trial and the MH-1b Trial
Trial No. of patients
No. of patients
Median follow-up (mos)CR PR NR PD Recurrence
MH-1
Age  65 yrs 87 84 (96%) 2 0 1 10 (12%) 91
CT-RT 41 40 1 0 0 4
CT-RT-CT 3 3 0 0 0 0
RT-CT 43 41 1 0 1 6
Age  65 yrs 6 6 0 0 0 0 59
CT-RT 3 3 0 0 0 —
CT-RT-CT 3 3 0 0 0 —
MH-1b 50 47 (94%) 0 2 1 5 (11%) 33
CR: complete response; PR: partial response; NR: no response; PD: progressive disease; CT: chemotherapy; RT: radiotherapy.
TABLE 4
Dose Intensity of Each Drug and of Whole Administered Regimens
(Vinblastine, Bleomycin, and Methotrexate [VBM] and Modiﬁed
VBM), Normalized to Planned VBM Times and Dosesa
MH-1: RT  VBM
(43 patients)
MH-1: VBM  RT
(41 patients)
MH-1b:
VbMp  RT
(50 patients)
VBL
0.80  0.22 — P  0.0001
P  0.0031 0.96  0.19 —
— P  0.0001 1.22  0.20
Bleo
0.82  0.20 — P  0.2962
P  0.0068 0.96  0.19 —
— P  0.0001 0.74  0.10
MTX
0.86  0.17 — P  0.0001
P  0.0026 0.99  0.17 —
— P  0.0001 1.25  0.13
Whole regimen (3 drugs)
0.82  0.17 — P  0.0001
P  0.0024 0.97  0.17 —
— P  0.0022 1.07  0.13
RT: radiotherapy; VBM: vinblastine, bleomycin, andmethotrexate; VbMp: modiﬁed VBM schedule; VBL:
vinblastine; Bleo: bleomycin; MTX: methotrexate.
a Values represent means  standard deviations. P values are shown for the differences between the
data in the corresponding rows and columns.
TABLE 5
World Health Organization Hematologic Toxicity Grades Recorded
during Administration of Vinblastine, Bleomycin, and Methotrexate
(VBM) or Modiﬁed VBM
Toxicity
Grade (no. of patients)
P value0 1 2 3 4
Hemoglobin
EF-RT  VBM
(46 patients) 34 7 4 1 0 0.081a
VBM  EF-RT
(41 patients) 39 2 0 0 0 0.209b
VbMp  IF-RT
(50 patients) 44 5 1 0 0 0.555c
Neutrophils
EF-RT  VBM
(46 patients) 13 17 9 6 1 0.001a
VBM  EF-RT
(41 patients) 34 4 2 1 0 0.105b
VbMp  IF-RT
(50 patients) 32 7 9 2 0 0.004c
Platelets
EF-RT  VBM
(46 patients) 39 2 4 0 1 0.385a
VBM  EF-RT
(41 patients) 40 1 0 0 0 0.105b
VbMp  IF-RT
(50 patients) 47 1 2 0 0 0.552c
EF-RT: extended-ﬁeld radiotherapy; VBM: vinblastine, bleomycin, and methotrexate; IF-RT: involved-
ﬁeld radiotherapy; VbMp: modiﬁed VBM schedule.
a EF-RT  VBM vs. VBM  EF-RT.
b VBM  EF-RT vs. VbMp  IF-RT.
c EF-RT  VBM vs. VbMp  IF-RT.
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toxic drugs tolerated in the MH-1b trial. It is notewor-
thy that growth factors never were used
prophylactically but were administered only in 7 of 10
patients who exhibited Grade 3 or 4 neutropenia.
Neurologic side effects, to both peripheral nerves
and autonomic nerves, were the main nonhemato-
logic toxicities, with no differences observed among
the three therapeutic subgroups identiﬁed. Defects or
full loss of tendon reﬂexes and difﬁculty walking were
observed in approximately 24% of patients, but sel-
dom were they severe enough to cause dose modiﬁ-
cations. Constipation was more frequent among pa-
tients older than age 55 years and, although not
absolutely frequent, was responsible for marked drug
dose reduction and administration delay. Five patients
had to be hospitalized for this problem. Alopecia was
rare. Nausea and emesis were controlled well with the
use of antiserotoninergic receptor drugs.
Overall, 12 patients experienced respiratory symp-
toms of different degrees of severity (see Table 6): 7 of
46 patients in the group treated on the EF-RT  VBM
schedule, 3 of 41 patients in the group treated on the
VBM  EF-RT schedule, and 2 of the 50 patients
treated in the VbMp  RT series. Five patients had
only cough and mild tachypnea and exhibited ﬁne,
reticular lesions on chest X-rays; three of those pa-
tients had forced vital capacity and 1-second forced
expiratory volume values that were lower than normal.
Four other patients exhibited exertional dyspnea with
transient cyanosis and ﬁne, bibasilar rales as well as
marked radiologic lesions and functional changes (Ta-
ble 6, Grade 2 column). Three patients experienced
severe respiratory failure with persistent hypoxia and
thus needed prolonged bed rest. Recovery was com-
plete in one patient and was very slow and partial in
the other two patients. The differences in frequency
and degree of toxicity reported in Table 6 are not
statistically signiﬁcant on their own but become sig-
niﬁcant when data from the 39 patients treated with
the RT  CT schedule are compared with data from
the other 87 patients who underwent the reversed
sequence, independent of RT ﬁeld extension and VBM
schedule. Moreover, a statistical trend toward lower
respiratory side effects in the MH-1b patients results
from the comparison with the MH-1 patients, testing
the effect of the whole set of treatment modiﬁcations
devised in the recent trial (bleomycin reduction, pred-
nisone addition, RT limitation, and prolonged interval
between CT and RT). Thus, if administering RT ﬁrst
appears to have greater adverse effects on lungs, de-
spite the fact that the numbers are small, then reduc-
tion of the bleomycin dose, the addition of pred-
nisone, and limitation of the irradiated volumes
probably contribute to further lower the pulmonary
toxicity. Finally, no differences related to smoking or
age were observed.
RT was limited to mantle-ﬁeld RT in 6 patients
and to inverted Y ﬁeld RT in the 4 patients with sub-
diaphragmatic involvement and consisted of STNI in
the remaining 77 patients from the MH-1 trial. In the
MH-1b study, RT was delivered strictly to the involved
lymphatic areas, which were below the diaphragm in 2
of 50 patients. Daily dose fractions ranged from 1.8 to
2.1 Gy, and total doses actually administered ranged
from 35 to 44 Gy (median, 38.4 Gy). No dose boosts
were delivered to selected areas. No early toxicity from
RT was observed apart from mild myelosuppression in
9 patients (only 2 patients on the MH-1b protocol) and
transient cutaneous changes in 11 patients. No acute
pulmonary or cardiac toxicity was recorded during RT.
Two secondary neoplasias were recorded, both in pa-
tients involved in the MH-1 study lung carcinoma in a
nonsmoking woman age 60 –years, who was diag-
nosed 6 years after the end of treatment, and myelo-
dysplasia in a man age 64 years, 11 years after therapy.
FFS was very similar in both trials, as shown in
Figure 1, with a minimal, statistically nonsigniﬁcant
difference in favor of the MH-1 patients, due to a
relatively higher rate of incomplete responses or NRs
and an earlier occurrence of recurrences in the MH-1b
trial (3 of 50 patients vs. 3 of 87 patients). However, the
OS was similar in both trials, as shown in Figure 2,
thanks to successful rescue of these patients with sec-
ond-line therapies.
DISCUSSION
In the last 15 years, VBM has been considered to be
one of the most attractive regimens, in that it fulﬁlls
TABLE 6
World Health Organization Pulmonary Toxicity Grades Recorded
after Different Chemotherapy and Radiotherapy Combinations
Toxicity
Grade (no. of patients)
P valuea0 1 2 3 4
MH-1 trial
EF-RT  VBM
(46 patients) 39 3 2 2 0 0.313b
VBM  EF-RT
(41 patients) 39 1 1 1 0 —
MH-1b trial
VbMp  IF-RT
(50 patients) 48 1 1 0 0 0.754c
EF-RT: extended-ﬁeld radiotherapy; VBM: vinblastine, bleomycin, and methotrexate; IF-RT: involved-
ﬁeld radiotherapy; VbMp: modiﬁed VBM schedule.
a For 1 vs. 2  3, P  0.027; for 1  2 vs. 3, P  0.081.
b EF-RT  VBM vs. VBM  EF-RT.
c VBM  EF-RT vs. VbMp  IF-RT.
2398 CANCER December 1, 2003 / Volume 98 / Number 11
several requirements of modern treatment for early-
stage HL—it avoids surgical staging, reduces the high
recurrence rate after RT alone, and spares patients
from having to receive alkylating agents and anthra-
cyclines. Indeed, VBM appeared very effective in
nearly all of the clinical trials in which it was tested,
but conﬂicting data have been collected regarding its
toxicity, probably due to slight (although critical) dif-
ferences in clinical settings, staging policies, treatment
protocols, and endpoints in clinical investigations.
In 1988, Horning et al.2 ﬁrst designed the VBM
schedule and demonstrated that in 67 patients with
surgically staged HL, including pathologic Stages IA to
IIIA, the effectiveness of such a CT regimen was able to
compensate for limiting RT to the involved ﬁelds only.
FFS rates at 5 years were 70% in the subtotal or total
lymph node irradiation arm (n  35) and 95% in the
arm treated with IF-RT plus VBM (n  32). Hemato-
logic and pulmonary toxicities were acceptable. It was
concluded that in patients with laparotomically staged
disease, a signiﬁcant reduction in the irradiated vol-
umes could be counterbalanced fully by subsequent
monthly administration of six cycles of VBM CT.
In 1994, the British National Lymphoma Investi-
gation (BNLI)15 reported on a study involving patients
with clinical Stage IA and IIA disease who were treated
with IF-RT plus VBM CT. In that study, CT was in-
tended to counterbalance both possible staging inac-
curacies and reductions in RT. The CR rate was 100%,
and only 2 of 30 patients (7%) developed recurrent
disease. Toxicity, both hematologic and pulmonary,
was severe, and the regimen was judged to be unsuit-
able for routine use. It is noteworthy that the BNLI
used a sandwich protocol in which two VBM cycles
were delivered before RT and four cycles were deliv-
ered after RT.
In 1996, the GISL5 published the preliminary results
of the MH-1 protocol for patients with clinical Stage IA
and IIA disease whose ﬁnal results are reported in the
current paper. The protocol was based on EF-RT and
VBM CT, with no age restriction for elderly patients. The
objective of the study was to assess whether the VBM
regimen could mitigate the expectable inaccuracy of a
merely clinical staging (also without lymphangiography).
Effectiveness was high in the ﬁrst 50 patients treated
(100% CR rate with a total of 5 recurrences). VBM was
administered after RT in 31 patients and before RT in 13,
whereas 6 patients received a sandwich treatment, with
3 cycles before RT and 3 cycles after RT. The schedule
recycled every 28 days, and the mean dose intensity
actually delivered was 0.82  0.18. Less toxicity was
observed compared with the BNLI study, and the cycles
appeared to be better tolerated when they were admin-
istered before RT than when they were administered
after RT or in the sandwich schedule. In particular, the
study demonstrated that pulmonary toxicity was related
primarily to the total dose of mediastinal irradiation and
secondarily to the total dose of bleomycin administered.
A subsequent randomized study by Horning et al.16
investigated the ability of the VBM regimen combined
with regional RT to balance the reduction in RT from
extended ﬁelds to involved ﬁelds in 78 patients with
clinical Stage IA and IIA disease. All patients experienced
CR, and the FFS rate was 92% for patients who were
treated with STLI alone and 93% for patients who re-
ceived VBM plus regional RT. In this group, RT was
sandwiched between the ﬁrst two VBM cycles and the
last four VBM cycles. In the last 4 cycles, the bleomycin
dose was decreased from 10 mg/m2 to 2.5 mg/m2. He-
FIGURE 1. Overall survival of patients in the Gruppo Italiano Studio Linfomi
MH-1 trial (thin line; n  87) and the subsequent MH-1b trial (thick line; n
 50; P  0.20). Only patients from the MH-1 trial who were of comparable
age (i.e., 65 years or younger) were included.
FIGURE 2. Failure-free survival of patients in the Gruppo Italiano Studio
Linfomi MH-1 (thin line; n  87) and MH-1b trials (thick line; n  50; P
 0.18).
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matologic toxicity was mild, and six patients had radio-
logic signs of radiation pneumonia. Although speciﬁc
data on the pulmonary toxicity recorded in this study
were not given but were cumulated with those from
other combination therapies, the authors concluded that
there was an inherent risk in combining major doses of
two potential pulmonary toxins—irradiation and bleo-
mycin. Thus, they did not advocate the routine use of
combined VBM and RT in clinical practice.
In 2000, Zinzani et al.17 reported the results of a pilot
study on 19 clinically evaluated elderly patients (median
age, 68 years; age range, 60–75 years) with different
stages of disease; the regimen consisted of VBM CT
combined with very limited RT that was delivered only
to the initial bulky mass after the completion of CT.
Fifteen patients responded completely, 3 (all with ad-
vanced-stage disease) responded only partially, and 1
did not respond at all. Two of three patients who devel-
oped recurrent disease achieved a second CR with a
different CT line. Five patients died, all of their disease.
Such results, which have to be considered satisfactory in
an elderly patient setting, were obtained with negligible
toxicity: mild hematologic side effects were observed in
30% of patients, and severe side effects ( ECOG Grade
3) were observed in only 1 patient. Transfusions, dose
reductions, and administration of growth factors never
were required. No pulmonary or cardiac toxicity was
recorded, not even in patients who received mediastinal
irradiation. The authors concluded that VBM is a safe
and effective therapeutic option for elderly patients.
The BNLI4 prolonged its experience with VBM by
treating another 30 early-stage, asymptomatic patients
with intermediate risk according to a speciﬁc prognostic
index. Patients were staged clinically and received RT
only to initially involved areas after the ﬁrst two VBM
cycles and before the last four VBM cycles. All patients
responded completely, ﬁve patients subsequently devel-
oped recurrent disease, and four patients were rescued
with different salvage treatments: one patient died of
disease. The VBM regimen also caused marked acute
hematologic toxicity in this second BNLI trial, and acute
pulmonary toxicity affected 47% of patients: thus, VBM
was abandoned deﬁnitively.
Finally, Martinelli et al.18 reported very good re-
sults with a sandwich protocol delivering 3 VBM cycles
followed by IF-RT and then by 4 more VBM cycles in
which the bleomycin dose was reduced from 10
mg/m2 to 6 mg/m2. Patients had clinical Stage IA or
IIA disease and were monitored carefully with regard
to pulmonary function. Forty-two of 43 patients re-
sponded completely, 7 patients developed recurrent
disease within the ﬁrst 3 years, and 5 patients were
rescued with alternative treatments. No patients expe-
rienced acute or late pulmonary toxicity. The authors
consider such a protocol effective and safe for patients
with early-stage disease; their only concern was the
length of the whole treatment.
Thus, with reference to surgical staging and EF-
RT, which was the standard therapy for patients with
favorable, early-stage HL 15 years ago, some studies
tested VBM CT only to reduce the extension of RT,2
others simply to avoid surgical staging (GISL-MH1
trial; see Gobbi et al.5 and current data), others for
both purposes in either young patients4,15,16,18 (GISL
MH-1b trial; current report) or elderly patients,17 or
even in both.5 All studies had excellent response rates
ranging from 94% to 100% in younger patients and
from 79% to 100% in elderly patients. Pulmonary tox-
icity was a major problem in some (but not all) of
those studies. Indeed, pulmonary toxicity was ob-
served when either the whole VBM regimen or at least
some cycles were administered after RT,2,4,15,16 as in
the sandwich combination. The so-called sandwich
schedule for delivering combined-modality therapy
was used commonly in the late 1970s and early 1980s
and then slowly was abandoned because of heavier
hematologic toxicity experienced in the cycles deliv-
ered after RT. The ﬁrst investigators who pointed out
the better tolerability of CT before RT were Kun et
al.,19 for mechlorethamine, vincristine, procarbazine,
and prednisone (MOPP), and Bonadonna et al.,20 for
ABVD. The results of the current study appear to con-
ﬁrm this observation as it relates to VBM, probably
due to a more toxic effect of drugs on bone marrow
that became hyperplastic after RT. It is noteworthy
that in the available reports on VBM therapy, pulmo-
nary toxicity generally was judged mild and tolerable,
independent of age, in the patients who received RT
after completion of the CT program5,17 (see also the
current data). In addition, the length of the rest period
between CT and RT may play a role in the development
of pulmonary toxicity, as demonstrated for hematologic
toxicity. In the GISL experience, the interval between the
end of CT and the start of RT was 26 days 8 days in the
MH-1 trial for patients who completed the CT program
before RT and 34 days  9 days in the corresponding
patients in theMH-1b trial. It is worth remembering that
in patients with HL, the ﬁrst combined treatment pro-
tocols21—which delivered variable numbers of MOPP
cycles after irradiation—recommended resting periods
of 6–8 to 8–12 weeks before RT. The Milan experience
with ABVD started20 with a resting period of 4–6 weeks
between ABVD, and it is noteworthy that hematologic
tolerability was improved and that there was no alarm-
ing pulmonary toxicity, despite the use of the same bleo-
mycin doses used in standard VBM and the administra-
tion of mantle irradiation to nearly all patients. It is
questionable whether the reduction of bleomycin in the
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last CT cycles truly can help to decrease pulmonary
toxicity: bleomycin doses were reduced in the MH-1b
GISL trial and in the study by Martinelli et al.18 (both
with exactly the same scheduled doses), in which pul-
monary toxicity was infrequent, whereas no advantage
in terms of lung tolerance was observed in the Stanford–
Kaiser Permanente experience, even after a greater re-
duction (2.5 mg/m2) in the last 4 cycles administered
after RT.
Apart from toxicity, there is a distinct concern re-
garding the effectiveness of the whole combined sched-
ule of modiﬁed VBM (VbMp) followed by IF-RT. Al-
though the CR rate (94%) may be considered acceptable
in the modern management of patients with HL, the
observed recurrence rate is not fully satisfactory, with a
mild excess in terms of early recurrences compared with
the preceding MH-1 experience. The increased dose in-
tensity of the administered VbMp may not have been
able to counterbalance fully the reduction of irradiation
to strictly involved sites, which resulted in a slightly
increased recurrence rate compared with VBM EF-RT.
More prolonged follow-up will be necessary to under-
stand the actual trend of the remission duration curve
and to design further modiﬁcations in the treatment
schedule. The use of a hypothetical CT regimen that
does not contain alkylating agents, anthracyclines, or
bleomycin combined with IF-RT appears to be the cur-
rent challenge in the treatment of patients with early-
stage HL to lower the risk of second malignancies, car-
diac incidents, and pulmonary toxicity. From this point
of view, the ABVD regimen itself, in which anthracycline
and bleomycin often are combined with RT, can only be
considered the current gold standard, and not an abso-
lute ideal. Future efforts should be aimed at designing a
more effective, less toxic CT regimen, because further
reductions in irradiation doses and ﬁelds for the fre-
quently involved mediastinum in these patients are
hardly feasible. Along with the intrinsic effects of bleo-
mycin on the lungs, both vinblastine and methotrexate
have been reported as factors that potentially enhance
the pulmonary effects of irradiation22 and can be con-
sidered for possible changes in the treatment schedule.
Some drugs, like vinorelbine and gemcitabine, also can
be considered as interesting additional or replacement
agents in the VBM schedule to come near the optimal CT
schedule for the combined treatment of patients with
early-stage HL.
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